Abstract:Epilepsy Currents, Ahead of Print. Severe Communication Delays are Independent of Seizure Burden and Persist Despite Contemporary Treatments in SCN1A+ Dravet Syndrome: Insights From the ENVISION Natural History StudyPerry MS, Scheffer IE, Sullivan J, Brunklaus A, Boronat S, Wheless JW, Laux L, Patel AD, Roberts CM, Dlugos D, Holder D, Knupp KG, Lallas M, Phillips S, Segal E, Smeyers P, Lal D, Wirrell E, Zuberi S, Brünger T, Wojnaroski M, Maru B, O'Donnell P, Morton M, James E, Vila MC, Huang N, Gofshteyn JS, Rico S. Epilepsia. 2024 Feb;65(2):322–337. Epub 2023 Dec 22. PMID: 38049202. doi:10.1111/epi.17850Objective: Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by high seizure burden, treatment-resistant epilepsy, and developmental stagnation. Family members rate communication deficits among the most impactful disease manifestations. We evaluated seizure burden and language/communication development in children with DS. Methods: ENVISION was a prospective, observational study evaluating children with DS associated with SCN1A pathogenic variants (SCN1A+ DS) enrolled at age ≤5 years. Seizure burden and antiseizure medications were assessed every 3 months and communication and language every 6 months with the Bayley Scales of Infant and Toddler Development 3rd edition and the parent-reported Vineland Adaptive Behavior Scales 3rd edition. We report data from the first year of observation, including analyses stratified by age at Baseline: 0:6-2:0 years:months (Y:M; youngest), 2:1-3:6 Y:M (middle), and 3:7-5:0 Y:M (oldest). Results: Between December 2020 and March 2023, 58 children with DS enrolled at 16 sites internationally. Median follow-up was 17.5 months (range = 0.0-24.0), with 54 of 58 (93.1%) followed for at least 6 months and 51 of 58 (87.9%) for 12 months. Monthly countable seizure frequency (MCSF) increased with age (median [minimum-maximum] = 1.0 in the youngest [1.0-70.0] and middle [1.0-242.0] age groups and 4.5 [0.0-2647.0] in the oldest age group), and remained high, despite use of currently approved antiseizure medications. Language/communication delays were observed early, and developmental stagnation occurred after age 2 years with both instruments. In predictive modeling, chronologic age was the only significant covariate of seizure frequency (effect size = .52, P = .024). MCSF, number of antiseizure medications, age at first seizure, and convulsive status epilepticus were not predictors of language/communication raw scores. Significance: In infants and young children with SCN1A+ DS, language/communication delay and stagnation were independent of seizure burden. Our findings emphasize that the optimal therapeutic window to prevent language/communication delay is before 3 years of age.

Dravet syndrome with favourable cognitive and behavioral development due to a novel SCN1A frameshift mutation

Clinical and Molecular Analysis of Epilepsy-Related Genes in Patients with Dravet Syndrome

[Genetic and phenotypic characteristics of SCN1A mutations in Dravet syndrome].

Clinical features and SCN1A mutation in 60 patients with Dravet syndrome

Analysis of SCN1A mutation and parental origin in patients with Dravet syndrome

Prognosis and follow-up study of 670 pediatric patients with Dravet syndrome

Early Clinical Features and Diagnosis of Dravet Syndrome in 138 Chinese Patients with SCN1A Mutations

Inherited SCN1A missense mutation in a Dravet Syndrome family: Neuropathological correlation, family screening and implications for adult carriers.

Advancements in Dravet Syndrome Therapeutics: A Comprehensive Look at Present and Future Treatment Horizons: A Focused Review

A Prime Example of the Role of Precision Medicine in Genetic Epilepsy

Dravet syndrome and its mimics: Beyond SCN1A

Study on the causative genes and analysis of genotypes and phenotypes of Dravet syndrome

Phenotype and gene mutation screening in familial Dravet syndrome

Clinical-electroencephalogram characteristics and its evolutionary process of Dravet syndrome

Neurodevelopmental defects in Dravet syndrome mice: targeting GABA-switch rescues behavioral dysfunctions but not seizures and mortality.

Neurodevelopmental defects in Dravet syndrome mice: selective rescue of behavioral alterations but not seizures by targeting GABA-switch

ENVISIONing a critical period to preserve development: communication delays in SCN1A+ dravet syndrome

Do All Roads Lead to Rome? Genes Causing Dravet Syndrome and Dravet Syndrome-Like Phenotypes

Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition

Cognitive and adaptive evaluation of 21 consecutive patients with Dravet syndrome

Insights into clinical phenotypes and treatment responses in a Small cohort of Taiwanese patients with SCN1A variants: A Preliminary study